Effect of nateglinide on the incidence of diabetes and cardiovascular events.

BACKGROUND: The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown. METHODS: In a double-blind, randomized clinical trial, we assigned 9306 participants with impaired glucose tolerance and either...

Täydet tiedot

Bibliografiset tiedot
Päätekijät:	Holman, R, Haffner, S, McMurray, J, Bethel, M, Holzhauer, B, Hua, T, Belenkov, Y, Boolell, M, Buse, J, Buckley, B, Chacra, A, Chiang, F, Charbonnel, B, Chow, C, Davies, M, Deedwania, P, Diem, P, Einhorn, D, Fonseca, V, Fulcher, G, Gaciong, Z, Gaztambide, S, Giles, T, Horton, E, Ilkova, H
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	2010

Effect of nateglinide on the incidence of diabetes and cardiovascular events.

Samankaltaisia teoksia